Boston Scientific Surpasses Market Growth with Strong Earnings and Buy Ratings

With a market cap of $155.2 billion, Boston Scientific Corporation (BSX) specializes in the development, manufacturing, and marketing of medical devices used across various interventional medical fields globally. Headquartered in Marlborough, Massachusetts, the company operates through two segments: MedSurg and Cardiovascular.

Over the past year, BSX shares have significantly outperformed the broader market. The stock has seen a gain of 45.7%, while the S&P 500 Index ($SPX) has only rallied by 12.3%. In the first quarter of 2025, BSX rose by 17.5%, contrasting with a 3.3% decline in the $SPX.

Narrowing the scope further, BSX has also outpaced the iShares U.S. Medical Devices ETF (IHI), which has increased by 9.6% over the last year and by 3.6% so far this year.

On April 22, Boston Scientific’s stock closed up more than 4% after the company announced its Q1 earnings. It raised its full-year net sales forecast to a range of 15% to 17%, up from a previous estimate of 12.5% to 14.5%. The company reported an earnings per share (EPS) of $0.75, exceeding analyst expectations by 11.9%.

For the fiscal year ending in December, analysts anticipate BSX’s EPS to grow by 15.9% year-over-year, reaching $2.91. The company has a solid earnings surprise history, having surpassed consensus estimates in each of the last four quarters.

Currently, BSX holds a consensus “Strong Buy” rating. Of the 28 analysts covering the stock, 25 recommend it as a “Strong Buy,” two suggest a “Moderate Buy,” and one rates it as a “Hold.”

This rating distribution has remained unchanged for the past three months. On April 25, Barclays plc (BCS) analyst Matt Miksic increased the firm’s price target for Boston Scientific to $125 from $118, maintaining an “Overweight” rating. The firm highlighted the solid results from the ADVANTAGE-AF study regarding the use of Farawave and Farapoint in treating persistent atrial fibrillation, which should facilitate FDA approval later this year.

The mean price target is set at $120.03, reflecting a potential 14.4% upside from current price levels. Furthermore, the street-high target of $135 indicates an impressive upside potential of 28.7%.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.